Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-12-08 pm EST
7.780 USD   +1.70%
12/01Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
PR
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/10HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société PROTAGONIST THERAPEUTICS, INC.
12/01Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology S..
PR
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/08PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
11/08Protagonist Therapeutics : Q3 Earnings Snapshot
AQ
11/02Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medic..
PR
09/20Protagonist Therapeutics Reports Granting of Inducement Award
PR
08/04Protagonist Therapeutics : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04Protagonist Therapeutics : Q2 Earnings Snapshot
AQ
08/04PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
08/04Protagonist Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corp..
PU
07/19Protagonist Therapeutics Reports Granting of Inducement Award
PR
06/02Protagonist Therapeutics, Inc : Submission of Matters to a Vote of Security Holders (form ..
AQ
06/01Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
PR
05/05PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
05/04Protagonist Therapeutics : Q1 Earnings Snapshot
AQ
04/26Protagonist Therapeutics : Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ul..
PU
04/26Protagonist Therapeutics, Inc : Financial Statements and Exhibits (form 8-K)
AQ
04/25Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in U..
PR
04/19Protagonist Therapeutics : Initial Statement of Beneficial Ownership (Form 3)
PU
04/19Protagonist Therapeutics Reports Granting of Inducement Awards
PR
04/13Protagonist Therapeutics, Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/31Protagonist Therapeutics, Inc : Change in Directors or Principal Officers (form 8-K)
AQ
03/28Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President ..
PR
03/23Protagonist Therapeutics, Inc : Change in Directors or Principal Officers (form 8-K)
AQ
03/16Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for D..
PR
02/28PROTAGONIST THERAPEUTICS, INC Management's Discussion and Analysis of Financial Condit..
AQ
02/28Protagonist Therapeutics : Reports Fourth Quarter and Full Year 2021 Financial Results and..
PU
02/28Protagonist Therapeutics : Q4 Earnings Snapshot
AQ
02/22Protagonist Therapeutics, Inc : Change in Directors or Principal Officers (form 8-K)
AQ
02/10Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Co..
PR
01/04/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
PR
2021Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
PR
2021Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
PR
2021Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
AQ
2021Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
PR
2021Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Pol..
AQ
2021Protagonist Therapeutics : Q3 Earnings Snapshot
AQ
2021PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
2021Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corp..
PU
2021Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Colla..
PR
2021Protagonist Therapeutics : to Present at the Jefferies Next Generation IBD Therapeutics Su..
PR
2021Protagonist Therapeutics : Announces Removal of FDA Clinical Hold on the Rusfertide Clinic..
PR
2021Protagonist Therapeutics : Announces Data from Phase 2 Rusfertide Study in Hereditary Hemo..
AQ
2021Protagonist Alert : Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of ..
BU
2021Protagonist Therapeutics : Reports FDA Clinical Hold on Rusfertide Clinical Development Pr..
AQ
2021Protagonist Therapeutics : Reports FDA Clinical Hold on Rusfertide Clinical Development Pr..
PU
2021Protagonist Therapeutics, Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Protagonist Therapeutics : Reports FDA Clinical Hold on Rusfertide Clinical Development Pr..
PR
2021Protagonist Therapeutics : Reports Granting of Inducement Awards
PR
2021Protagonist Therapeutics : Appoints Scott Plevy, M.D., Executive Vice President and Therap..
PR
2021Protagonist Therapeutics : Announces Resolution of Contract Dispute with Zealand Pharma
PR
2021Protagonist Therapeutics, Inc : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021Protagonist Therapeutics : Q2 Earnings Snapshot
AQ
2021Protagonist Therapeutics : Reports Second Quarter 2021 Financial Results and Recent Compan..
PU
2021Protagonist Therapeutics : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
2021Protagonist Therapeutics : Reports Second Quarter 2021 Financial Results and Recent Compan..
PR
2021Protagonist Therapeutics, Inc : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021Protagonist Therapeutics : Announces Amendment of Agreement with Janssen Biotech for the C..
PR
2021Protagonist Therapeutics : Reports Granting of Inducement Award
PR
2021Protagonist Therapeutics Inc. : Announces Closing of $132.2 Million Public Offering of Com..
AQ
2021Protagonist Therapeutics, Inc. : Announces Closing of $132.2 Million Public Offering of Co..
PR
2021Protagonist Therapeutics, Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Protagonist Therapeutics : Announces Pricing of $115 Million Upsized Public Offering of Co..
PR
2021Protagonist Therapeutics : Announces Proposed Public Offering of Common Stock
PR
2021Protagonist Therapeutics, Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Protagonist Therapeutics : Announces Updated Phase 2 Data Supporting Long-Term Efficacy of..
AQ
2021Protagonist Therapeutics : Announces Updated Phase 2 Data Supporting Long-Term Efficacy of..
PR
2021Protagonist Therapeutics : to Host Investor Conference Call and Webcast to Discuss Updated..
PR
2021Protagonist Therapeutics : Receives FDA Breakthrough Therapy Designation for Rusfertide in..
AQ
2021Protagonist Therapeutics, Inc : Submission of Matters to a Vote of Security Holders (form ..
AQ
2021Protagonist Therapeutics : Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Re..
PR
2021Protagonist Therapeutics : Announces Presentation of Updated Results from Phase 2 Study of..
AQ
2021Protagonist Therapeutics : Q1 Earnings Snapshot
AQ
2021Protagonist Therapeutics : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
2021Protagonist Therapeutics : Reports First Quarter 2021 Financial Results and Provides Corpo..
PR
1  2  3  4Next
Upcoming event on PROTAGONIST THERAPEUTICS, INC.